AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 255: R166-R173, 1988;
0363-6119/88 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janiak, P.
Right arrow Articles by Brody, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janiak, P.
Right arrow Articles by Brody, M. J.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 255, Issue 1 166-R173, Copyright © 1988 by American Physiological Society


ARTICLES

Central interactions between aldosterone and vasopressin on cardiovascular system

P. Janiak and M. J. Brody
Department of Pharmacology, University of Iowa, Iowa City 52242.

Although the presence of mineralocorticoid binding sites have been demonstrated in brain, little is known about their physiological role. The purpose of this study was to evaluate possible interactions between a relatively short 2-day central infusion of aldosterone (5 ng/h) and a diverse group of centrally acting pressor agents. The intracerebroventricular infusion of aldosterone selectively attenuated the pressor response produced by the injection of arginine vasopressin (AVP, 10-400 ng) into the lateral ventricle without altering the responses to ventricular administration of 50-200 ng angiotensin II (ANG II), 150 ng carbachol, and 0.5 and 1 M hypertonic sodium chloride. No aldosterone-vasopressin interaction occurred in rats receiving a simultaneous central infusion of aldosterone and RU 28318 [7 beta-hydroxy-3-oxo-7 alpha-propyl(17 alpha)-pregn-4-ene-21-potassium carboxylate], a specific mineralocorticoid receptor antagonist. Baroreflex reactivity and the pressor response to intravenous AVP were not modified by the aldosterone treatment, indicating that overall cardiovascular reactivity was not depressed. Because the vascular reactivity of the mesenteric artery to AVP and norepinephrine remained unchanged after 2 days of central aldosterone infusion, and because plasma levels of aldosterone were not altered, the selective inhibition by this mineralocorticoid of the central AVP response appears to be purely central in origin. This specific central effect of aldosterone is mediated through interaction with mineralocorticoid receptors.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Ngarmukos and R. J. Grekin
Nontraditional aspects of aldosterone physiology
Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Rahmouni, M. Barthelmebs, M. Grima, J.-L. Imbs, and W. De Jong
Brain Mineralocorticoid Receptor Control of Blood Pressure and Kidney Function in Normotensive Rats
Hypertension, May 1, 1999; 33(5): 1201 - 1206.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online